Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.

The purpose of this article is to document the discussions at the 2010 European Workshop on Equivalence Determinations for Orally Inhaled Drugs for Local Action, cohosted by the International Society for Aerosols in Medicine (ISAM) and the International Pharmaceutical Consortium on Regulation and Science (IPAC-RS). The article summarizes current regulatory approaches in Europe, the United States, and Canada, and presents points of consensus as well as ongoing debate in the four major areas: in vitro testing, pharmacokinetic and pharmacodynamic studies, and device similarity. Specific issues in need of further research and discussion are also identified.

[1]  J. Shuster,et al.  Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. , 2006, The Journal of pediatrics.

[2]  Svetlana Lyapustina,et al.  Non-impactor-Based Methods for Sizing of Aerosols Emitted from Orally Inhaled and Nasal Drug Products (OINDPs) , 2011, AAPS PharmSciTech.

[3]  H. Bisgaard,et al.  Lung function measurement in awake young children. , 1995, The European respiratory journal.

[4]  Svetlana Lyapustina,et al.  Relative Precision of Inhaler Aerodynamic Particle Size Distribution (APSD) Metrics by Full Resolution and Abbreviated Andersen Cascade Impactors (ACIs): Part 2—Investigation of Bias in Extra-Fine Mass Fraction with AIM-HRT Impactor , 2010, AAPS PharmSciTech.

[5]  H. Magnussen,et al.  Comparison of the Oropharyngeal Deposition of Inhaled Ciclesonide and Fluticasone Propionate in Patients With Asthma , 2005, Journal of clinical pharmacology.

[6]  K. Midha,et al.  The bioequivalence of highly variable drugs and drug products. , 2005, International journal of clinical pharmacology and therapeutics.

[7]  Stephen W. Stein,et al.  SELECTION AND VALIDATION OF CASCADE IMPACTOR TEST METHODS , 2004 .

[8]  R. Pauwels,et al.  Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals. , 2001, American journal of respiratory and critical care medicine.

[9]  P. O'Byrne,et al.  Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. , 1999, American journal of respiratory and critical care medicine.

[10]  R. Hermann,et al.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.

[11]  R. Ahrens,et al.  Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  Y. Yin,et al.  Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays , 2004, European Journal of Clinical Pharmacology.

[13]  D. Pavia,et al.  An in vitro study to assess facial and ocular deposition from Respimat Soft Mist inhaler. , 2007, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[14]  B. Lipworth,et al.  Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment , 1999, Clinical endocrinology.

[15]  H. Chan,et al.  Method to introduce mannitol powder to intubated patients to improve sputum clearance. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[16]  Peter R. Byron,et al.  Dose emissions from marketed dry powder inhalers , 1995 .

[17]  L. Lewis,et al.  A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. , 2002, The Journal of allergy and clinical immunology.

[18]  K. Nikander,et al.  Validation of a new breathing simulator generating and measuring inhaled aerosol with adult breathing patterns. , 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[19]  A. Fuglsang,et al.  Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[20]  A. Tattersfield,et al.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects , 2000, Thorax.

[21]  M. Frosolono,et al.  Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. , 2000, Chest.

[22]  S. Newman,et al.  Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device. , 2002, International journal of pharmaceutics.

[23]  H. Ortega,et al.  Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing , 2009, Clinical therapeutics.

[24]  M. J. Needham,et al.  Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[25]  A. Pietinalho,et al.  Delivery Devices for Inhaled Asthma Medication , 1996, Clinical Immunotherapeutics.

[26]  H. Chrystyn,et al.  Determination of the Relative Bioavailability of Salbutamol to the Lungs Following Inhalation from Dry Powder Inhaler Formulations Containing Drug Substance Manufactured by Supercritical Fluids and Micronization , 2007, Pharmaceutical Research.

[27]  M. Hertog,et al.  Lung deposition of budesonide from the novel dry powder inhaler Airmax. , 2002, Respiratory medicine.

[28]  Jolyon Mitchell,et al.  Analysis of cascade impactor mass distributions. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[29]  A. Tattersfield,et al.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. , 1997, Thorax.

[30]  Hak-Kim Chan,et al.  In vitro/in vivo comparisons in pulmonary drug delivery. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[31]  A A ANDERSEN,et al.  NEW SAMPLER FOR THE COLLECTION, SIZING, AND ENUMERATION OF VIABLE AIRBORNE PARTICLES, , 1958, Journal of bacteriology.

[32]  H. Möllmann,et al.  Pharmacokinetic/Pharmacodynamic Aspects of Aerosol Therapy using Glucocorticoids as a Model , 1997, Journal of clinical pharmacology.

[33]  Lawrence X. Yu,et al.  In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung Diseases , 2009, The AAPS Journal.

[34]  D. McRobbie,et al.  In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[35]  R. Pauwels,et al.  Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. , 2007, Respiratory medicine.

[36]  2.9.18. PREPARATIONS FOR INHALATION: AERODYNAMIC ASSESSMENT OF FINE PARTICLES , 2004 .

[37]  R. Pauwels,et al.  Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. , 1997, The European respiratory journal.

[38]  Svetlana Lyapustina,et al.  Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2—Evaluation of a method for determining equivalence , 2008, AAPS PharmSciTech.

[39]  Svetlana Lyapustina,et al.  Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: Background for a statistical method , 2007, AAPS PharmSciTech.

[40]  B. Lipworth,et al.  Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide. , 2011, British journal of clinical pharmacology.

[41]  Svetlana Lyapustina,et al.  STANDARDS , REGULATIONS AND CURRENT PRACTICES FOR ORALLY INHALED AND NASAL DRUG PRODUCTS , 2009 .

[42]  A. Tattersfield,et al.  Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. , 2006, British journal of clinical pharmacology.

[43]  P. Uster,et al.  Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. , 2009, International journal of pharmaceutics.

[44]  Svetlana Lyapustina,et al.  Relative Precision of Inhaler Aerodynamic Particle Size Distribution (APSD) Metrics by Full Resolution and Abbreviated Andersen Cascade Impactors (ACIs): Part 1 , 2010, AAPS PharmSciTech.

[45]  R. Reba,et al.  In Vitro and In Vivo Characteristics , 1989 .

[46]  Warren H. Finlay,et al.  On the suitability of k–ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment , 2000 .

[47]  Svetlana Lyapustina,et al.  Product Lifecycle Approach to Cascade Impaction Measurements , 2011, AAPS PharmSciTech.

[48]  Svetlana Lyapustina,et al.  Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 3: Final report on a statistical procedure for determining equivalence , 2008, AAPS PharmSciTech.

[49]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[50]  R. Pauwels,et al.  Pharmacokinetic and Pharmacodynamic Properties of Inhaled Beclometasone Dipropionate Delivered Via Hydrofluoroalkane-Containing Devices , 2005, Clinical pharmacokinetics.

[51]  A. Bye,et al.  The Relationship between Systemic Exposure to Fluticasone Propionate and Cortisol Reduction in Healthy Male Volunteers , 2000, Clinical pharmacokinetics.

[52]  Svetlana Lyapustina,et al.  Improved Quality Control Metrics for Cascade Impaction Measurements of Orally Inhaled Drug Products (OIPs) , 2009, AAPS PharmSciTech.

[53]  Svetlana Lyapustina,et al.  Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[54]  H. Bisgaard.  A metal aerosol holding chamber devised for young children with asthma. , 1995, The European respiratory journal.

[55]  D. J. Finney.  Statistical Method in Biological Assay , 1966 .